Work

Identification of bi-epitopic anti-SQSTM1 monoclonal antibodies with therapeutic efficacy in experimental sepsis and rheumatoid arthritis

Year: 2026
Type: article
Abstract: Background Sequestosome-1 (SQSTM1/p62) is a multifunctional signaling adaptor that integrates ubiquitin sensing, selective autophagy, and inflammatory signaling. Although antibody-mediated neutralization of extracellular SQSTM1 has previously shown therapeutic benefit in experimental sepsis, the epitope specificity, structural basis of target recognition, and therapeutic potential of antibodies directed against alternative SQSTM1 domains remain unknown. Methods Recombinant human SQSTM1 protein was generated to immunize BALB/c and C57BL/6 mice. Monoclonal antibodies (mAbs) were characterized by sequencing, structural modeling, epitope mapping, antibody-antigen docking, and paratope footprint analysis. Therapeutic efficacy was evaluated in murine models of polymicrobial sepsis induced by cecal ligation and puncture (CLP) and collagen antibody-induced arthritis (CAIA). Mechanistic studies were performed using Cytokine Antibody Arrays of arthritic tissue lysate and immune cell-conditioned culture media. Results Ten SQSTM1-reactive mAbs were generated and demonstrated cross-reactivity with human and murine SQSTM1 proteins. In contrast to a previously reported antibody recognizing an epitope within the SQSTM1 intrinsically disordered region (IDR), epitope mapping identified two highly conserved immunodominant regions located within the N-terminal Phox and Bem1 (PB1) and the C-terminal ubiquitin-associated (UBA) domains. Unexpectedly, all antibodies exhibited bi-epitopic recognition despite the substantial separation of these epitopes within the SQSTM1 sequence. Structural modeling revealed a shared paratope footprint that accommodated both PB1- and UBA-derived peptides. Therapeutic administration of representative antibodies significantly improved survival in CLP-induced sepsis, whereas delayed antibody treatment also significantly attenuated established CAIA. Mechanistically, SQSTM1 blockade reduced joint expression of VCAM-1, P-selectin, MIP-1γ, soluble TNFRI and TNFRII, indicating broad suppression of inflammatory pathways controlling endothelial activation, leukocyte recruitment, and TNF signaling. Consistent with a pathogenic role in arthritis, SQSTM1 levels were elevated in inflamed joints from CAIA mice and in the circulation of patients with rheumatoid arthritis (RA). Recombinant procathepsin-L (pCTS-L) induced SQSTM1 release, whereas anti-SQSTM1 mAbs suppressed SQSTM1-induced production of cytokines (IFN-γ and IL-1α) and chemokines (e.g., GRO-α, MCP-2, and MIP-1δ), supporting a pro-inflammatory role for extracellular SQSTM1 downstream of the HMGB1–pCTS-L pathway. Conclusions These findings identify PB1 and UBA domain epitopes as therapeutically actionable regions of SQSTM1 and reveal a previously unrecognized class of bi-epitopic anti-SQSTM1 mAbs with efficacy in experimental sepsis and inflammatory arthritis.
Language: English
Subfield: Immunology
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236065731
FWCI:
Cites: 50
Cited by:
Related to: 10
Parts: 1